Mutational analysis of the estrogen receptor ligand-binding domain: Influence of ligand structure and stereochemistry on transactivation

被引:15
|
作者
Kohno, H
Bocchinfuso, WP
Gandini, O
Curtis, SW
Korach, KS
机构
[1] Lab. of Repro. and Devmtl. Toxicol., Natl. Inst. of Environ. Hlth. Sci., National Institutes of Health, Research Triangle Park, NC 27709
关键词
D O I
10.1677/jme.0.0160277
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mouse estrogen receptor (mER) exhibits ligand stereochemical specificity for indenestrol A (IA), a stilbestrol estrogen. IA has a chiral C3 methyl group, and the mER preferentially binds the S-enantiomer (IA-S). resulting in elevated biological activity when compared with the IA-R enantiomer. To elucidate the mechanisms for this stereochemical recognition, we have constructed a series of mERs with individual amino acid substitutions at Met521, His528, Met532, and Val537. The abilities of yeast-expressed wild-type and mutant mERs to transactivate an estrogen-responsive reporter gene construct were measured in the presence of diethylstilbestrol (DES) and IA enantiomers. The concentration of IA-S required to induce half-maximal transactivation by wild-type mER was 10-fold lower than IA-R, which is attributed to the 15-fold greater binding affinity for IA-S. Wild-type mER displayed similar dose-response curves for IA-R and demethyl IA, which lacks a C3 methyl group, demonstrating that the presence and correct orientation of the C3 methyl group on the IA compound is required for high-affinity ligand binding and transcriptional activity. Each mutant exhibited a reduced preference for IA-S enantiomer with respect to transactivation, suggesting that this region of the mER functions in ligand stereochemical recognition and activation. A mutation at Met532 diminished DES- and IA-S-induced transactivation by 7.5-fold and 40-fold respectively, with minimal change on their binding affinity. These data suggest that Met532 is required for transactivation induced by the potent agonist, IA-S, and the M532G mutation effectively uncouples IA-S ligand binding from transactivation. Use of these stereochemically different ligands in combination with mutagenesis of the mER demonstrates that ligand structure could influence transactivation by specifically altering the conformation of the mER AF-2 region.
引用
收藏
页码:277 / 285
页数:9
相关论文
共 50 条
  • [41] Structure of the ligand-binding domain of the EphB2 receptor at 2 Å resolution
    Goldgur, Yehuda
    Paavilainen, Sari
    Nikolov, Dimitar
    Himanen, J. P.
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2009, 65 : 71 - 74
  • [42] Solution structure of the chick TGFβ type II receptor ligand-binding domain
    Marlow, MS
    Brown, CB
    Barnett, JV
    Krezel, AM
    JOURNAL OF MOLECULAR BIOLOGY, 2003, 326 (04) : 989 - 997
  • [43] Separable features of the ligand-binding domain determine the differential subcellular localization and ligand-binding specificity of glucocorticoid receptor and progesterone receptor
    Wan, YH
    Coxe, KK
    Thackray, VG
    Housley, PR
    Nordeen, SK
    MOLECULAR ENDOCRINOLOGY, 2001, 15 (01) : 17 - 31
  • [44] A canonical structure for the ligand-binding domain of nuclear receptors
    Wurtz, JM
    Bourguet, W
    Renaud, JP
    Vivat, V
    Chambon, P
    Moras, D
    Gronemeyer, H
    NATURE STRUCTURAL BIOLOGY, 1996, 3 (01): : 87 - 94
  • [45] ANALYSIS OF LIGAND-BINDING SPECIFICITY OF RECEPTOR CHIMERAS
    CATTERALL, WA
    SCIENCE, 1989, 243 (4888) : 236 - 237
  • [46] A MODIFIED ESTROGEN-RECEPTOR LIGAND-BINDING DOMAIN AS AN IMPROVED SWITCH FOR THE REGULATION OF HETEROLOGOUS PROTEINS
    LITTLEWOOD, TD
    HANCOCK, DC
    DANIELIAN, PS
    PARKER, MG
    EVEN, GI
    NUCLEIC ACIDS RESEARCH, 1995, 23 (10) : 1686 - 1690
  • [47] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Gonzalez, Thomas L.
    Hancock, Molly
    Sun, Siqi
    Gersch, Christina L.
    Larios, Jose M.
    David, Waddie
    Hu, Jiantao
    Hayes, Daniel F.
    Wang, Shaomeng
    Rae, James M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 611 - 622
  • [48] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Thomas L. Gonzalez
    Molly Hancock
    Siqi Sun
    Christina L. Gersch
    Jose M. Larios
    Wadie David
    Jiantao Hu
    Daniel F. Hayes
    Shaomeng Wang
    James M. Rae
    Breast Cancer Research and Treatment, 2020, 180 : 611 - 622
  • [49] Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression
    Valentine, JE
    Kalkhoven, E
    White, R
    Hoare, S
    Parker, MG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) : 25322 - 25329
  • [50] ANALYSIS OF THE SEQUENCE HOMOLOGY AND VARIABILITY IN THE LIGAND-BINDING DOMAIN OF THE EGF RECEPTOR FAMILY
    CAMPION, S
    FASEB JOURNAL, 1994, 8 (07): : A1407 - A1407